Mr. Weng is Chairman and President of TTIC, a foreign investment company headquartered in Beijing, China. Originally a regional office of Tippins Technologies, TTIC became an independent company in 2005. In his 50-year career in the steel industry, Mr. Weng has developed deep knowledge and rich experience in the metals industry both in China and in the United States.
Mr. Weng earned his Master’s degree in Metallurgical Engineering at Beijing Science and Technology University and began his career as a plant engineer at Shanghai Alloy. He went on to become an engineer and technical negotiator at Baoshan Iron and Steel, working on major capital projects with foreign suppliers.
Moving to the United States in 1980, he earned an M.S. in Chemistry from Northeast Louisiana University and became an American citizen. He worked for Pennsylvania Engineering Corporation as its China Business Manager, supervising PECOR’s entry into the Chinese market.
His areas of expertise include project development, contract administration, and project financing. His sales experience is global, ranging from East Asia to South America to Europe.
Currently Senior Executive Vice President and General Manager, Cardiac Devices, for Curative Medical Technology, Inc., in Santa Clara, California, Ms. Chiu studied and began her professional career in Shanghai. She earned a B.S. in Mechanical Engineering from Dong Hua University and worked as a Research & Development Engineer for Synthetic Fiber Research Institute in Shanghai.
In the United States, she earned an M.S. in Material Engineering from the University of Maryland and a Certificate in Biomaterial Processing from Massachusetts Institute of Technology. Before joining Curative Medical Technology, Ms. Chiu held positions with Kimberly-Clark Corp., C.R. Bard, Inc., Advanced Cardiovascular Systems, Inc., Guidant Corporation, and Abbott Laboratories.
She has published 19 U.S. patents and patent applications related to medical devices.
Dr. Hou has 16 years of experience in microbiology, molecular biology, and pharmacology research. Currently, he is Chairman of the Board of Shanghai Haohai Biotechnology Company, Ltd. and has also held research and development and executive positions with the China Worldbest Group. He has served on the Board of C & O Hong Kong Pharmaceutical Technology (Holdings) Ltd. and been Scientific Adviser to Nanjing Meirui Pharmaceutical Co., Inc. In these positions he has developed extensive experience in mergers and acquisitions, international negotiations, and technique evaluation.
Dr. Hou earned his B.S. in Biology at Nanjing University, one of the oldest and most prestigious institutions of higher learning in China. In the United States, he earned a M.S. in Microbiology and a Ph.D. in Molecular Biology from Ohio University. He has also had Executive MBA training at the University of British Columbia in Canada.
He has been honored to be named to the “Overseas Excellent Researcher Program” of the Chinese Academy of Sciences and to the “Overseas Excellent Talent” program of the Shanghai government. He has also served as a Professor of Molecular Pharmacology at Shanghai Institute of Material Medica of the Chinese Academy of Sciences.
He has received research funding grants in the United States and in China and has authored over 20 scientific publications.